What are the clear contraindications for the use of Milizumab?

Milikizumab(Mirikizumab) is a monoclonal antibody targeting the IL-23 receptor and is widely used to treat immune-related diseases such as ulcerative colitis. Although the drug has shown good efficacy in clinical treatment, like other biological agents, militizumab also has certain contraindications and should not be used in certain circumstances.

First of all, one of the main contraindications to militizumab is patients who are allergic to any component of the drug. If the patient is known to be allergic to militizumab or its excipients, use of this drug may cause severe allergic reactions, including anaphylactic shock, rash, itching, etc. Therefore, before starting treatment, doctors need to carefully ask patients whether they have any history of allergies, especially to biologics or monoclonal antibody drugs.

Second, militizumab is not suitable for patients with severe active infection. For example, tuberculosis, serious bacterial, fungal, or viral infections are considered contraindications to militizumab. This is because militizumab modulates the immune response by inhibiting the activity of IL-23, and suppression of the immune system may make patients more susceptible to infection. For patients experiencing acute or chronic active infection, use of militizumab may increase the risk of infection or even lead to serious complications. Therefore, the use of militizumab should only be considered after ensuring that the patient's infection has been effectively controlled.

Additionally, militizumab is contraindicated in patients with active liver disease. Militizumab may cause abnormal liver function, especially when patients have liver disease. The use of the drug may increase the burden on the liver and lead to further damage to liver function. Therefore, for patients with severe liver disease or liver failure, doctors generally avoid using militizumab or closely monitor liver function indicators during treatment.

Reference materials:https://omvoh.lilly.com/